| Study |
Reference |
|
Alsfouk (Levetiracetam), 2022
|
Alsfouk, B.A. Patterns of antiseizure medication prescription in pregnancy and maternal complications in women with epilepsy: A retrospective study in Saudi Arabia Saudi Pharm. J. 2022; 30:205-.
|
|
Alsfouk (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2021
|
Alsfouk, B.A. Antiseizure medications use during pregnancy and congenital malformations: A retrospective study in Saudi Arabia Saudi Pharm. J. 2021; 29:939-.
|
|
Alsfouk (Levetiracetam) (Controls unexposed, sick), 2021
|
Alsfouk, B.A. Antiseizure medications use during pregnancy and congenital malformations: A retrospective study in Saudi Arabia Saudi Pharm. J. 2021; 29:939-.
|
|
AlSheikh (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020
|
AlSheikh Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes. Neurosciences (Riyadh) 2020; 25:32-37
|
|
AlSheikh (Levetiracetam) (Controls unexposed, sick), 2020
|
AlSheikh Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes. Neurosciences (Riyadh) 2020; 25:32-37
|
|
Arkilo (Levetiracetam), 2015
|
Arkilo D Pregnancy and neurodevelopmental outcomes with in-utero antiepileptic agent exposure. A pilot study. Eur J Paediatr Neurol 2015;19:37-40
|
|
Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013
|
Artama M Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland. Drug Saf 2013;36:359-69
|
|
Artama (Levetiracetam) (Controls unexposed, disease free), 2013
|
Artama M Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland. Drug Saf 2013;36:359-69
|
|
Artama (Levetiracetam) (Controls unexposed, sick), 2013
|
Artama M Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland. Drug Saf 2013;36:359-69
|
|
Aydin (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020
|
Aydin, E. Retrospective evaluation of pregnancy outcomes with maternal epilepsy Journal of Clinical Obstetrics and Gynecology 2020; 30:20-.
|
|
Aydin (Levetiracetam) (Controls unexposed, sick), 2020
|
Aydin, E. Retrospective evaluation of pregnancy outcomes with maternal epilepsy Journal of Clinical Obstetrics and Gynecology 2020; 30:20-.
|
|
Babic (Levetiracetam), 2014
|
Babic Postnatal concerns in children born to women with juvenile myoclonic epilepsy. In: European Congress on Epileptology. vol. 55. Stockholm: Epilepsia; 2014: 128
|
|
Bank (Levetiracetam) (Mixed indications), 2017
|
Bank Placental passage of antiepileptic drugs at delivery and neonatal outcomes. Epilepsia 2017; 58:e82-e86
|
|
Bech (Levetiracetam) (Mixed indications), 2018
|
Bech In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. J Neurol Neurosurg Psychiatry 2018; 89:1324-1331
|
|
Bjørk (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2022
|
Bjørk Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. JAMA Neurol 2022; :
|
|
Bjørk (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2018
|
Bjørk Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In Utero. JAMA Neurol 2018; 75:160-168
|
|
Bjørk (Levetiracetam) (Controls unexposed NOS), 2022
|
Bjørk Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. JAMA Neurol 2022; :
|
|
Bjørk (Levetiracetam) (Controls unexposed, disease free), 2018
|
Bjørk Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In Utero. JAMA Neurol 2018; 75:160-168
|
|
Bjørk (Levetiracetam) (Controls unexposed, sick), 2018
|
Bjørk Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In Utero. JAMA Neurol 2018; 75:160-168
|
|
Bjørk (Levetiracetam) (Controls unexposed, sick), 2022
|
Bjørk Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. JAMA Neurol 2022; :
|
|
Blotière (Levetiracetam) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019
|
Blotière Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019; 93:e167-e180
|
|
Blotière (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2019
|
Blotière Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019; 93:e167-e180
|
|
Bromley (Levetiracetam), 2016
|
Bromley RL Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology 2016;87:1943-1953
|
|
Bromley (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023
|
Bromley Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study. Epilepsia 2023; 64:2454-2471
|
|
Bromley (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023
|
Bromley Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study. Epilepsia 2023; 64:2454-2471
|
|
Cohen (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023
|
Christensen Prenatal exposure to valproate and risk of congenital malformations-Could we have known earlier?-A population-based cohort study. Epilepsia 2021; 62:2981-2993 Cohen Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations. Ann Neurol 2023; 93:551-562
|
|
Cohen (Levetiracetam) (Epilepsy) (Controls unexposed, NOS), 2023
|
Christensen Prenatal exposure to valproate and risk of congenital malformations-Could we have known earlier?-A population-based cohort study. Epilepsia 2021; 62:2981-2993 Cohen Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations. Ann Neurol 2023; 93:551-562
|
|
Coste (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020
|
Blotière Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. BMJ Open 2020; 10:e034829 Coste Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep 2020; 10:17362
|
|
Coste (Levetiracetam) (Controls unexposed, NOS), 2020
|
Coste Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep 2020; 10:17362
|
|
Dreier (Levetiracetam), 2021
|
Dreier, J. Prenatal exposure to antiseizure medication and intrauterine growth restriction in offspring of women with epilepsy. Epilepsia 2021; 62:6-.
|
|
Dreier (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023
|
Dreier Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. JAMA Neurol 2023; 80:568-577
|
|
Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023
|
Dreier Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. JAMA Neurol 2023; 80:568-577
|
|
Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012
|
Hernández-Díaz Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9 Lewis B. Holmes, M.D. (Director) Risk of malformations for specific AED in monotherapy and the control groups (Annual Update for 2022) https://www.aedpregnancyregistry.org/ (Consulted 05/2022)
|
|
Hernández-Díaz (Levetiracetam) (Controls unexposed, disease free), 2012
|
Hernández-Díaz Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9 Lewis B. Holmes, M.D. (Director) Risk of malformations for specific AED in monotherapy and the control groups (Annual Update for 2022) https://www.aedpregnancyregistry.org/ (Consulted 05/2022)
|
|
Hosny (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2021
|
Hosny Risk factors of fetal deaths and major birth defects in newborns of women with epilepsy: An Egyptian prospective study. Epilepsy Behav 2021; 123:108251
|
|
Hosny (Levetiracetam) (Controls unexposed, sick), 2021
|
Hosny Risk factors of fetal deaths and major birth defects in newborns of women with epilepsy: An Egyptian prospective study. Epilepsy Behav 2021; 123:108251
|
|
Huber-Mollema (Levetiracetam), 2019
|
Huber-Mollema Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy. Epilepsia 2019; 60:1069-1082
|
|
Husebye (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020
|
Husebye Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in utero - the Norwegian Mother and Child Cohort Study. Eur J Neurol 2020; 27:667-675
|
|
Husebye (Levetiracetam) (Controls unexposed, disease free), 2020
|
Husebye Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in utero - the Norwegian Mother and Child Cohort Study. Eur J Neurol 2020; 27:667-675
|
|
Husebye (Levetiracetam) (Controls unexposed, sick), 2020
|
Husebye Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in utero - the Norwegian Mother and Child Cohort Study. Eur J Neurol 2020; 27:667-675
|
|
Källén (Levetiracetam) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013
|
Källén B The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 2013;6:1221-86
|
|
Källén (Levetiracetam) (Controls unexposed, NOS) (Indications NOS), 2013
|
Källén B The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 2013;6:1221-86
|
|
Kilic (Levetiracetam) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014
|
Kilic D Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014;55:1714-21
|
|
Kilic (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2014
|
Kilic D Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014;55:1714-21
|
|
Kilic (Levetiracetam) (Controls unexposed, sick) (Mixed indications), 2014
|
Kilic D Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014;55:1714-21
|
|
Koc (Levetiracetam), 2018
|
Koc Fetal safety of levetiracetam use during pregnancy. Acta Neurol Belg 2018; 118:503-508
|
|
Li (Levetiracetam) (Controls exposed to LTG), 2023
|
He Pregnancy outcome in women with epilepsy in Western China: A prospective hospital based study. Epilepsy Behav 2017; 74:10-14 Li Pregnancy characteristics and adverse outcomes in offspring of women with epilepsy: a prospective registry study from Mainland China. Front Neurol 2023; 14:1195003
|
|
Li (Levetiracetam) (Controls unexposed, sick), 2023
|
He Pregnancy outcome in women with epilepsy in Western China: A prospective hospital based study. Epilepsy Behav 2017; 74:10-14 Li Pregnancy characteristics and adverse outcomes in offspring of women with epilepsy: a prospective registry study from Mainland China. Front Neurol 2023; 14:1195003
|
|
Mari (Levetiracetam), 2022
|
Mari Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy? Neurol Sci 2022; 43:1993-2001
|
|
Meador (Controls exposed to LTG), 2023
|
Meador Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study. JAMA Neurol 2021; 78:927-936 Meador Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study. Lancet Neurol 2023; 22:712-722
|
|
Meador (Controls unexposed, disease free), 2023
|
Meador Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study. JAMA Neurol 2021; 78:927-936 Meador Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study. Lancet Neurol 2023; 22:712-722
|
|
Meador (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020
|
Meador Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology 2020; 94:e1502-e1511
|
|
Meador (Levetiracetam) (Controls unexposed, disease free), 2020
|
Meador Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology 2020; 94:e1502-e1511
|
|
Meador (Levetiracetam) (Controls unexposed, sick), 2020
|
Meador Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology 2020; 94:e1502-e1511
|
|
Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006
|
Morrow J Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-8
|
|
Morrow (Levetiracetam) (Controls unexposed, sick), 2006
|
Morrow J Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-8
|
|
Pekoz (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023
|
Pekoz Birth outcomes in pregnant women with epilepsy: A Nationwide multicenter study from Turkiye. Epilepsia 2023; 64:2310-2321
|
|
Pekoz (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023
|
Pekoz Birth outcomes in pregnant women with epilepsy: A Nationwide multicenter study from Turkiye. Epilepsia 2023; 64:2310-2321
|
|
Richards (Levetiracetam) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2019
|
Richards Developmental outcomes at age four following maternal antiepileptic drug use. Epilepsy Behav 2019; 93:73-79
|
|
Richards (Levetiracetam) (Controls unexposed, NOS) (Indications NOS), 2019
|
Richards Developmental outcomes at age four following maternal antiepileptic drug use. Epilepsy Behav 2019; 93:73-79
|
|
Shallcross (Levetiracetam), 2011
|
Shallcross Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011; 76:383-9
|
|
The NAAED (Controls exposed to Lamotrigine, sick) (Indications NOS), 2022
|
Hernández-Díaz Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9 Lewis B. Holmes, M.D. (Director) Risk of malformations for specific AED in monotherapy and the control groups (Annual Update for 2022) https://www.aedpregnancyregistry.org/ (Consulted 05/2022)
|
|
The NAAED (Controls unexposed, disease free) (Indications NOS), 2022
|
Hernández-Díaz Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9 Lewis B. Holmes, M.D. (Director) Risk of malformations for specific AED in monotherapy and the control groups (Annual Update for 2022) https://www.aedpregnancyregistry.org/ (Consulted 05/2022)
|
|
Thomas (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2021
|
Keni Teratogenicity of antiepileptic dual therapy: Dose-dependent, drug-specific, or both? Neurology 2018; 90:e790-e796 Thomas Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India. Epilepsia 2017; 58:274-281 Thomas Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP). Seizure 2021; 93:127-132
|
|
Thomas (Levetiracetam) (Controls unexposed, disease free), 2021
|
Thomas Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India. Epilepsia 2017; 58:274-281
|
|
Thomas (Levetiracetam) (Controls unexposed, sick), 2021
|
Thomas Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India. Epilepsia 2017; 58:274-281 Thomas Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP). Seizure 2021; 93:127-132
|
|
Tomson (Levetiracetam), 2018
|
Martinez Ferri Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. Neurologia 2018; 33:78-84 Tomson Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018; 17:530-538 Tomson T Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-17
|
|
Tomson (Levetiracetam), 2015
|
Tomson T Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP. Neurology 2015;85:580-8
|
|
Trivedi (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2018
|
Trivedi Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India. Epilepsy Res 2018; 146:50-53
|
|
Trivedi (Levetiracetam) (Controls unexposed, sick), 2018
|
Trivedi Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India. Epilepsy Res 2018; 146:50-53
|
|
Vajda (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2019
|
Vajda Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure 2010; 19:558-61 Vajda Teratogenicity of the newer antiepileptic drugs--the Australian experience. J Clin Neurosci 2012; 19:57-9 Vajda The prescribing of antiepileptic drugs for pregnant Australian women. Aust N Z J Obstet Gynaecol 2012; 52:49-53 Vajda Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol. Scand. 2013; 128:228-34 Vajda The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010; 51:805-10 Vajda The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007; 47:468-74 Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11 Vajda FJ The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 2014;130:234-8
|
|
Vajda (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2018
|
Vajda Anti-epileptic drug exposure and risk of foetal death in utero. Acta Neurol Scand 2018; 137:20-23
|
|
Vajda (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013
|
Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11 Vajda Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol. Scand. 2013; 128:228-34
|
|
Vajda (Levetiracetam) (Controls unexposed, sick), 2019
|
Vajda Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure 2010; 19:558-61 Vajda Teratogenicity of the newer antiepileptic drugs--the Australian experience. J Clin Neurosci 2012; 19:57-9 Vajda The prescribing of antiepileptic drugs for pregnant Australian women. Aust N Z J Obstet Gynaecol 2012; 52:49-53 Vajda Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol. Scand. 2013; 128:228-34 Vajda The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010; 51:805-10 Vajda The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007; 47:468-74 Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11 Vajda FJ The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 2014;130:234-8
|
|
Vajda (Levetiracetam) (Controls unexposed, sick), 2018
|
Vajda Anti-epileptic drug exposure and risk of foetal death in utero. Acta Neurol Scand 2018; 137:20-23
|
|
Vajda (Levetiracetam) (Controls unexposed, sick), 2013
|
Vajda Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol Scand 2013; 128:228-34 Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11
|
|
Van Marter (Levetiracetam) (Controls unexposed, disease free), 2021
|
Van Marter, L.J. Neonatal Outcomes in the MONEAD Study of Pregnant Women with Epilepsy Journal of Pediatrics: X 2021; 7:514-.
|
|
Van Marter (Levetiracetam) (Controls unexposed, sick), 2021
|
Van Marter, L.J. Neonatal Outcomes in the MONEAD Study of Pregnant Women with Epilepsy Journal of Pediatrics: X 2021; 7:514-.
|
|
Veiby (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2014
|
Veiby Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J. Neurol. 2014; 261:579-88
|
|
Veiby (Levetiracetam) (Controls unexposed, disease free), 2014
|
Veiby Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J. Neurol. 2014; 261:579-88
|
|
Veiby (Levetiracetam) (Controls unexposed, sick), 2014
|
Veiby Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J. Neurol. 2014; 261:579-88
|
|
Videman (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2016
|
Videman Evidence for spared attention to faces in 7-month-old infants after prenatal exposure to antiepileptic drugs. Epilepsy Behav 2016; 64:62-68
|
|
Videman (Levetiracetam) (Controls unexposed, disease free), 2016
|
Videman Evidence for spared attention to faces in 7-month-old infants after prenatal exposure to antiepileptic drugs. Epilepsy Behav 2016; 64:62-68
|
